Technologies
PDF


WARF: P05114US

TTNPB Analogs Useful for Preventing or Treating Cancer


INVENTORS -

Margaret Clagett-Dame, Robert Curley, Michael Collins, Victoria Abzianidze

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing retinoic acid analogs with reduced toxicity for the treatment of cancer.
OVERVIEWRetinoic acid and a number of its analogs have shown some ability to prevent and treat cancer. One of the most potent is 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid, or TTNPB. However, toxicity has been a significant obstacle to the development of these compounds.
THE INVENTIONUW-Madison researchers have developed less toxic TTNPB analogs for the prevention or treatment of breast cancer. One such analog, 4-HBTTNPB, inhibits the proliferation of tumor cells. Because it binds poorly to the retinoic acid receptor and the retinoic X receptor, it is less likely to cause adverse side effects than TTNPB.
APPLICATIONS
  • Prevention or treatment of cancer, including breast cancer
KEY BENEFITS
  • Stable and easy to synthesize
  • Likely to have fewer side effects
STAGE OF DEVELOPMENTThe development of this technology was supported by WARF Accelerator. WARF Accelerator selects WARF's most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones. WARF believes that these technologies are especially attractive opportunities for licensing.
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Intellectual Property
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.